BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Imbria Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Imbria Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07023614-658@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IMB-101 (Ninerafaxstat): Phase 2 readout est. (NCT07023614)
DESCRIPTION:IMB-101 (Ninerafaxstat)\, phase 2\, Hypertrophic Cardiomyopathy
 .\nStudy: A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in 
 Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy\nEst
 imated primary completion: December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ninerafaxstat#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07023614
URL:https://assetmemo.bio/drug/ninerafaxstat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
